Clinical Trial Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, variants, or PubMed publications.

Have questions, comments or suggestions? - Let us know!

Email us at : ckbsupport@jax.org

NCT ID NCT02342379
Title TH-302 in Combination With Bevacizumab for Glioblastoma
Recruitment Completed
Gender both
Phase Phase II
Variant Requirements No
Sponsors The University of Texas Health Science Center at San Antonio
Indications

glioblastoma

Therapies

Bevacizumab + Evofosfamide

Age Groups: adult
Covered Countries USA


No variant requirements are available.